.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,518,949

« Back to Dashboard

Claims for Patent: 8,518,949

Title:Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin .delta. and rifaximin .epsilon. useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Inventor(s): Viscomi; Giuseppe Claudio (Sasso Marconi, IT), Campana; Manuela (Bologna, IT), Confortini; Donatella (Calderara di Reno, IT), Barbanti; Maria Miriam (Bologna, IT), Braga; Dario (Bologna, IT)
Assignee: ALFA Wassermann S.p.A. (Alanno (PE), IT)
Application Number:13/488,345
Patent Claims: 1. Rifaximin in polymorphic form .delta., wherein the polymorph .delta. is obtained by the process of: reacting a molar equivalent of rifamycin O with an excess of 2-amino-4-methylpyridine in a first solvent mixture, comprising water and ethyl alcohol in volumetric ratios between 1:1 and 2:1, for between 2 and 8 hours at a temperature between 40.degree. C. and 60.degree. C. to obtain a first reaction mixture; treating the first reaction mixture at room temperature with a solution of ascorbic acid in a mixture of water, ethyl alcohol and concentrated aqueous hydrochloric acid to obtain a second reaction mixture; adding concentrated aqueous solution of hydrochloric acid to the second reaction mixture to bring the pH to 2.0 thereby obtaining a first suspension; filtering the first suspension to obtain a first solid; washing the first solid with the first solvent mixture to obtain raw rifaximin; dissolving the raw rifaximin in ethyl alcohol at a temperature between 45.degree. C. and 65.degree. C.; forming a precipitate by adding water and lowering the temperature of the mixture to between 50.degree. C. and 0.degree. C. while stirring for between 4 and 36 hours to obtain a second suspension; filtering the second suspension to obtain a second solid; washing the second solid with water and drying it under vacuum or under normal pressure, with or without a drying agent, at a temperature between room temperature and 105.degree. C., for between 2 and 72 hours to a water content of between 2.5% and 6% (w/w), wherein the rifaximin polymorphic form .delta. is free from other polymorphic forms of rifaximin and has x-ray powder diffraction pattern peaks at about 5.7.degree..+-.0.2, 12.1.degree..+-.0.2, and 17.0.degree..+-.0.2 2-.theta..

2. The rifaximin of claim 1, wherein the excess of 2-amino-4-methylpyridine is present at from 2.0 to 15 molar equivalents compared to the rifamycin O.

3. The rifaximin of claim 1, wherein the amount of water added to form the precipitate is between 15% and 70% by weight compared to the weight of ethyl alcohol used for the dissolution in the previous step.

4. The rifaximin of claim 1, wherein when the water is added to form the precipitate, the temperature is lowered to between 28.degree. C. and 32.degree. C.

5. The rifaximin of claim 4, wherein the process further comprises: stirring the second suspension at between 40.degree. C. and 50.degree. C. for between 6 and 24 hours followed by cooling the mixture to 0.degree. C., for between 15 minutes and one hour to obtain a third suspension; and filtering the third suspension and drying the obtained solid to a water content of between 2.5% and 6% (w/w).

6. The rifaximin of claim 5, wherein the water content is between 3.0% and 4.5%.

7. Rifaximin in polymorphic form .epsilon., wherein the polymorph .epsilon. is obtained by the process of: reacting a molar equivalent of rifamycin O with an excess of 2-amino-4-methylpyridine in a first solvent mixture, comprising water and ethyl alcohol in volumetric ratios between 1:1 and 2:1, for between 2 and 8 hours at a temperature between 40.degree. C. and 60.degree. C. to obtain a first reaction mixture; treating the first reaction mixture at room temperature with a solution of ascorbic acid in a mixture of water, ethyl alcohol and concentrated aqueous hydrochloric acid to obtain a second reaction mixture; adding concentrated aqueous solution of hydrochloric acid to the second reaction mixture to bring the pH to 2.0 thereby obtaining a first suspension; filtering the first suspension to obtain a first solid; washing the first solid with the first solvent mixture to obtain raw rifaximin; dissolving the raw rifaximin in ethyl alcohol at a temperature between 45.degree. C. and 65.degree. C.; forming a precipitate by adding water and lowering the temperature of the mixture to between 50.degree. C. and 0.degree. C. while stirring for between 4 and 36 hours to obtain a second suspension; filtering the second suspension to obtain a second solid; washing the second solid with water and drying it under vacuum or under normal pressure, with or without a drying agent, at a temperature between room temperature and 105.degree. C., for between 2 and 72 hours, wherein the rifaximin polymorphic form .epsilon. is free from other polymorphic forms of rifaximin and has x-ray powder diffraction pattern peaks at about 8.2.degree..+-.0.2, 12.4.degree..+-.0.2, and 16.3.degree..+-.0.2 2-.theta..

8. The rifaximin of claim 7, wherein the excess of 2-amino-4-methylpyridine is present at from 2.0 to 3.5 molar equivalents compared to the rifamycin O.

9. The rifaximin of claim 7, wherein the amount of water added to form the precipitate is between 15% and 70% by weight compared to the weight of ethyl alcohol used for the dissolution in the previous step.

10. The rifaximin of claim 7, wherein when the water is added to form the precipitate, the temperature is lowered to between 28.degree. C. and 32.degree. C.

11. The rifaximin of claim 10, wherein the process further comprises: stirring the second suspension at between 40.degree. C. and 50.degree. C. for between 6 and 24 hours followed by cooling the mixture to 0.degree. C. for between 15 minutes and one hour to obtain a third suspension; and filtering the third suspension and drying the obtained solid to obtain rifaximin polymorphic form .epsilon..

12. A solid pharmaceutical composition comprising a therapeutically effective amount of rifaximin .delta. and a pharmaceutically acceptable excipient, together disposed in a formulation for oral administration, wherein the rifaximin polymorphic form .delta. has x-ray powder diffraction pattern peaks at about 5.7.degree..+-.0.2, 12.1.degree..+-.0.2, and 17.0.degree..+-.0.2 2-.theta..

13. The pharmaceutical composition according to claim 12, wherein the excipient is selected from the group consisting of diluting, binding, lubricating, disintegrating, coloring, flavoring, and sweetening agents.

14. The pharmaceutical composition according to claim 12 wherein the formulation for oral administration is selected from the group consisting of coated or uncoated tablet, hard or soft gelatin capsule, sugar-coated pill, lozenge, wafer sheet, pellet, and powder in sealed packet.

15. A solid pharmaceutical composition comprising a therapeutically effective amount of rifaximin .delta. and a pharmaceutically acceptable excipient, together disposed in a formulation for topical administration, wherein the rifaximin polymorphic form .delta. has x-ray powder diffraction pattern peaks at about 5.7.degree..+-.0.2, 12.1.degree..+-.0.2, and 17.0.degree..+-.0.2 2-.theta..

16. The pharmaceutical composition according to claim 15, wherein the formulation for topical administration is selected, from the group consisting of ointment, pomade, cream, gel and lotion.

17. A solid pharmaceutical composition comprising a therapeutically effective amount of rifaximin .epsilon. and a pharmaceutically acceptable excipient, together disposed in a formulation for oral administration, wherein the rifaximin polymorphic form .epsilon. has x-ray powder diffraction pattern peaks at about 8.2'.+-.0.2, 12.4.degree..+-.0.2, and 16.3.degree..+-.0.2 2-.theta..

18. The pharmaceutical composition according to claim 17, wherein the excipient is selected from the group consisting of diluting, binding, lubricating, disintegrating, coloring, flavoring, and sweetening agents.

19. The pharmaceutical composition according to claim 17 wherein the formulation for oral administration is selected from the group consisting of coated or uncoated tablet, hard or soft gelatin capsule, sugar-coated pill, lozenge, wafer sheet, pellet, and powder in sealed packet.

20. A solid pharmaceutical composition comprising a therapeutically effective amount of rifaximin .epsilon. and a pharmaceutically acceptable excipient, together disposed in a formulation for topical administration, wherein the rifaximin polymorphic form .epsilon. has x-ray powder diffraction pattern peaks at about 8.2.degree..+-.0.2, 12.4.degree..+-.0.2, and 16.3.degree..+-.0.2 2-.theta..

21. The pharmaceutical composition according to claim 20, wherein the formulation for topical administration is selected from the group consisting of ointment, pomade, cream, gel and lotion.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc